Genetic Testing Solution Guidelines
Our Solution
The genetic testing market is growing rapidly, with more than 175,000 tests available today. Our Genetic Testing Management solution addresses the significant complexity that exists in genetic testing by ensuring that medical necessity criteria has been met for tests that may frequently be used inappropriately.
Preview Genetic Testing Clinical Guidelines for July 1, 2025 Implementation:
Autism Spectrum Disorder_Intellectual Disability Panel Analysis
Bladder Cancer Treatment and Recurrence Algorithmic Tests
Bladder_Urinary Tract Cancer Diagnostic Algorithmic Tests
Breast Cancer Extended Endocrine Therapy Algorithmic Tests_
Breast Cancer Prognostic Algorithmic Tests_
Breast Cancer Treatment and Prognostic Algorithmic Tests_
Breast DCIS Prognostic Algorithmic Tests
Broad Molecular Profiling Panel Tests via Circulating Tumor DNA_ctDNA
Broad Molecular Profiling Panels For Hematologic Malignancies and Myeloid Malignancy Panels
Cancer of Unknown Primary Gene Expression Profiling Tests
Chromosomal Microarray Analysis_CMA_for Pregnancy Loss
Chromosomal Microarray Analysis_CMA_for Prenatal Diagnosis
CM Analysis for Dev Delay_Intellectual Disability, Autism Spectrum DO, or Congenital Anomalies
Colorectal Cancer Prognostic Algorithmic Tests
Comprehensive Arrhythmia and Cardiomyopathy_Sudden Cardiac or Unexplained Death_Panels
Comprehensive Arrhythmia Panels
Comprehensive Cardiomyopathy Panels
Comprehensive Connective Tissue Disorders Multigene Panel
Comprehensive Kidney Disease Panels
Cutaneous Melanoma Diagnostic Algorithmic Tests
Cutaneous Melanoma Risk Assessment Algorithmic Tests_
Donor-Derived Cell-free DNA for Heart Transplant Rejection
Emerging Evidence Lung Cancer Treatment Algorithmic Tests
Emerging Evidence Rheumatoid Arthritis Algorithmic Tests
Evidence-Based Lung Cancer Risk Assessment Algorithmic Tests
Evidence-Based Lung Cancer Treatment Algorithmic Tests
Evidence-Based Prostate Cancer Risk Assessment and Diagnostic Algorithmic Tests
Evidence-Based Solid Tumor Minimal Residual Disease_MRD_Testing
Expanded Carrier Screening Panels
Familial Hypercholesterolemia_FH_Panels
Hereditary Breast and_or Ovarian Cancer Susceptibility Panels
Hereditary Dystonia Multigene Panel_
Hereditary GI_Colon Cancer Susceptibility Panels
Hereditary Polyposis Susceptibility Panels
HPV-Related Solid Tumor Minimal Residual Disease_MRD_Testing
Hypertrophic Cardiomyopathy Panels
Inflammatory Bowel Disease_Crohn’s Disease Diagnostic Algorithmic Tests
Lung Cancer Focused Molecular Profiling Panels
Lung Cancer Focused Panel Tests via Circulating Tumor DNA_ctDNA
Mitochondrial Genome Sequencing, Deletion_Duplication, and_or Nuclear Gene Panel
MLH1, MSH2, MSH6, PMS2, and_or EPCAM Sequencing and_or Deletion_Duplication Analysis
Monogenic Diabetes_Including Maturity Onset Diabetes of the Young _MODY_Panels
Myeloproliferative Neoplasms_MPNs_Panels
Noonan Spectrum Disorders_RASopathies Multigene Panel
Other Covered Immune, Autoimmune, and Rheumatoid Disorders
Ovarian Cancer Treatment Algorithmic Tests
Ovarian Cancer Diagnostic Algorithmic Tests
Pan-Cancer Hereditary Cancer Susceptibility Panels
Post Heart Transplant Gene Expression Panels for Rejection Risk via Peripheral Blood
Prenatal Cell-free DNA Testing for Fetal RhD Genotyping
Prenatal Cell-free DNA Testing for Single-gene Disorders
Prostate Cancer Treatment and Prognostic Algorithmic Tests
Reanalysis of Exome or Genome Sequencing Data
Thyroid Cancer Diagnostic Algorithmic Tests
Tumor Specific BCR-ABL1 FISH, Qualitative, and Quantitative Tests
Tumor-Type Agnostic Solid Tumor Molecular Profiling Panels_
Uveal Melanoma Prognostic Algorithmic Tests